Back to Report Store Home

Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need

  • Published: Aug-2017
  • Report Code: GBIHC449MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Overall Pharmaceutical Industry, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987–2016 7

Figure 2: Hematological Disorders Therapeutics Market, First-in-Class and Non-First-in-Class Products, Sales Performance After Marketing Approval, 2006–2013 ($m) 9

Figure 3: Hematological Disorders Therapeutics Market, Global, Complement Pathway Overview, 2017 17

Figure 4: Hematological Disorders Therapeutics Market, Global, Marketed Product Overview, 2017 25

Figure 5: Overall Pharmaceutical Market, Global, Developmental Pipeline Overview, 2017 27

Figure 6: Hematological Disorders Therapeutics Market, Global, Pipeline by Indication, 2017 28

Figure 7: Hematological Disorders Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type, 2017 30

Figure 8: Hematological Disorders Therapeutics Market, Global, Pipeline by Molecular Target, 2017 32

Figure 9: Hematological Disorders Therapeutics Market, Global, Overall Pharmaceutical Industry First-in-Class Pipeline by Therapy Area, 2017 33

Figure 10: Hematological Disorders Therapeutics Market, Global, Overall Pharmaceutical Industry First-in-Class Pipeline by Therapy Area, 2017 34

Figure 11: Hematological Disorders Therapeutics Market, Global, First-in-Class Pipeline for Hematological disorders by Stage of Development and Molecule Type, 2017 35

Figure 12: Hematological Disorders Therapeutics Market, Global, First-in-Class Pipeline for Hematological disorders by Stage of Development and Molecule Type, 2017 36

Figure 13: Hematological Disorders Therapeutics Market, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2017 37

Figure 14: Hematological Disorders Therapeutics Market, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2017 38

Figure 15: Hematological Disorders Therapeutics Market, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2017 39

Figure 16: Hematological Disorders Therapeutics Market, Global, First-in-Class Developmental Programs in Sickle Cell Disease Pipeline, 2017 40

Figure 17: Hematological Disorders Therapeutics Market, Global, First-in-Class Developmental Programs in Anemias Pipeline, 2017 40

Figure 18: Hematological Disorders Therapeutics Market, Global, First-in-Class Developmental Programs in Paroxysmal Nocturnal Hemoglobinuria Pipeline, 2017 41

Figure 19: Hematological Disorders Therapeutics Market, Global, First-in-Class Developmental Programs in Bleeding Disorders Pipeline, 2017 41

Figure 20: Hematological Disorders Therapeutics Market, Global, First-in-Class Developmental Programs in Immune Cell Disorders Pipeline, 2017 42

Figure 21: Hematological Disorders Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Sickle Cell Disease, 2017 45

Figure 22: Hematological Disorders Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Anemias, 2017 45

Figure 23: Hematological Disorders Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Paroxysmal Nocturnal Hemoglobinuria, 2017 45

Figure 24: Hematological Disorders Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Bleeding Disorders, 2017 46

Figure 25: Hematological Disorders Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Immune Cell Disorders, 2017 46

Figure 26: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 48

Figure 27: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 50

Figure 28: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 51

Figure 29: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 53

Figure 30: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 54

Figure 31: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 56

Figure 32: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 57

Figure 33: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 59

Figure 34: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 60

Figure 35: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 61

Figure 36: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 61

Figure 37: Hematological Disorders Therapeutics Market, Global, Pipeline Programs Targeting XXX, 2017 61

Figure 38: Pharmaceutical Market, Global, Industry-Wide Deals by Stage of Development, 2006–2014 63

Figure 39: Pharmaceutical Market, Global, Industry Licensing Deal Values by Stage of Development, 2006–2014 64

Figure 40: Hematological Disorders Therapeutics Market, Global, Licensing Deals by Region and Value, 2006–2017 65

Figure 41: Hematological Disorders Therapeutics Market, Global, Licensing Deals by Stage of Development, 2006–2017 66

Figure 42: Hematological Disorders Therapeutics Market, Global, Licensing Deals Valued Above $25m, 2006–2017 66

Figure 43: Hematological Disorders Therapeutics Market, Global, Co-Development Deals by Region and Value, 2006–2017 67

Figure 44: Hematological Disorders Therapeutics Market, Global, Co-Development Deals by Stage of Development, 2006–2017 68

Figure 45: Hematological Disorders Therapeutics Market, Global, Co-Development Deals by Molecule Type, 2006–2017 68

Figure 46: Hematological Disorders Therapeutics Market, Global, Co-Development Deals by Molecular Target, 2006–2017 69

Figure 47: Hematological Disorders Therapeutics Market, Global, Co-Development Deals Valued Above $25m, 2006–2017 69

Figure 48: Hematological Disorders Therapeutics Market, Global, First-in-class Programs in Active Development Involved in Previous Deals, 2017 70

Figure 49: Hematological Disorders Therapeutics Market, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2017 71

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards